Cliff Asness's PTCT Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 342,106 shares of PTC Therapeutics, Inc. (PTCT) worth $23.31 M, representing 0.01% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 44 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in PTCT, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2025, adding 255,674 shares. Largest reduction occurred in Q3 2025, reducing 205,860 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's PTC Therapeutics (PTCT) Holding Value Over Time
Track share changes against reported price movement
Quarterly PTC Therapeutics (PTCT) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +179 | Add 0.05% | 342,106 | $68.13 |
| Q4 2025 | +10,671 | Add 3.22% | 341,927 | $75.96 |
| Q3 2025 | -205,860 | Reduce 38.33% | 331,256 | $61.37 |
| Q2 2025 | +124,093 | Add 30.05% | 537,116 | $48.84 |
| Q1 2025 | +255,674 | Add 162.49% | 413,023 | $50.96 |
| Q4 2024 | -32,230 | Reduce 17.00% | 157,349 | $45.14 |
| Q3 2024 | +120,667 | Add 175.10% | 189,579 | $37.10 |
| Q2 2024 | +52,019 | Add 307.93% | 68,912 | $30.58 |
| Q1 2024 | -11,930 | Reduce 41.39% | 16,893 | $29.09 |
| Q4 2023 | -81,578 | Reduce 73.89% | 28,823 | $27.56 |
| Q3 2023 | +37,831 | Add 52.13% | 110,401 | $22.41 |
| Q2 2023 | +5,611 | Add 8.38% | 72,570 | $40.67 |
| Q1 2023 | +4,565 | Add 7.32% | 66,959 | $48.44 |
| Q4 2022 | +49,475 | Add 382.96% | 62,394 | $38.17 |
| Q3 2022 | +904 | Add 7.52% | 12,919 | $50.24 |
| Q2 2022 | -23,960 | Reduce 66.60% | 12,015 | $40.03 |
| Q1 2022 | +30,748 | Add 588.25% | 35,975 | $37.30 |
| Q4 2021 | +5,227 | New Buy | 5,227 | $39.79 |
| Q2 2021 | -4,583 | Sold Out | 0 | $0.00 |
| Q1 2021 | -6,172 | Reduce 57.39% | 4,583 | $47.35 |
| Q4 2020 | -17,029 | Reduce 61.29% | 10,755 | $60.99 |
| Q3 2020 | -49,898 | Reduce 64.23% | 27,784 | $46.75 |
| Q2 2020 | -8,976 | Reduce 10.36% | 77,682 | $50.75 |
| Q1 2020 | -2,546 | Reduce 2.85% | 86,658 | $44.61 |
| Q4 2019 | +54,175 | Add 154.66% | 89,204 | $48.02 |
| Q3 2019 | -25,584 | Reduce 42.21% | 35,029 | $33.83 |
| Q2 2019 | -182,015 | Reduce 75.02% | 60,613 | $45.01 |
| Q1 2019 | -10,232 | Reduce 4.05% | 242,628 | $37.64 |
| Q4 2018 | +141,602 | Add 127.27% | 252,860 | $34.32 |
| Q3 2018 | +66,154 | Add 146.67% | 111,258 | $47.00 |
| Q2 2018 | +27,526 | Add 156.59% | 45,104 | $33.72 |
| Q1 2018 | -5,747 | Reduce 24.64% | 17,578 | $27.08 |
| Q4 2017 | -50,289 | Reduce 68.31% | 23,325 | $16.68 |
| Q3 2017 | +23,060 | Add 45.61% | 73,614 | $20.01 |
| Q2 2017 | +38,330 | Add 313.56% | 50,554 | $18.34 |
| Q1 2017 | +12,224 | New Buy | 12,224 | $9.82 |
| Q2 2016 | -85,397 | Sold Out | 0 | $0.00 |
| Q1 2016 | +85,397 | New Buy | 85,397 | $6.44 |
| Q4 2015 | -47,823 | Sold Out | 0 | $0.00 |
| Q3 2015 | -47,900 | Reduce 50.04% | 47,823 | $26.70 |
| Q2 2015 | +13,447 | Add 16.34% | 95,723 | $48.13 |
| Q1 2015 | +29,900 | Add 57.09% | 82,276 | $60.84 |
| Q4 2014 | +9,676 | Add 22.66% | 52,376 | $51.78 |
| Q3 2014 | +42,700 | New Buy | 42,700 | $44.00 |
Cliff Asness's PTC Therapeutics Investment FAQs
Cliff Asness first purchased PTC Therapeutics, Inc. (PTCT) in Q3 2014, acquiring 42,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held PTC Therapeutics, Inc. (PTCT) for 44 quarters since Q3 2014.
Cliff Asness's largest addition to PTC Therapeutics, Inc. (PTCT) was in Q1 2025, adding 413,023 shares worth $21.05 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 342,106 shares of PTC Therapeutics, Inc. (PTCT), valued at approximately $23.31 M.
As of the Q1 2026 filing, PTC Therapeutics, Inc. (PTCT) represents approximately 0.01% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in PTC Therapeutics, Inc. (PTCT) was 537,116 shares, as reported at the end of Q2 2025.